Ask AI
ProCE Banner Activity

DoxyPEP: Grappling with a Double-Edged Sword

Clinical Thought

Recent data at EACS from trials of DoxyPEP for protection from sexually transmitted infections (STIs) affirm its efficacy but also highlight a fundamental trade-off: Protection at the cost of contribution to antimicrobial resistance (AMR). Learn what implications this may have for Canada and beyond.

Released: November 25, 2025

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from Gilead Sciences, Inc., Merck & Co., Inc., Rahway, NJ, USA, and ViiV Healthcare.

Gilead Sciences, Inc.

Merck & Co., Inc., Rahway, NJ, USA

ViiV Healthcare

Target Audience

This activity is intended for physicians, pharmacists, registered nurses, and other healthcare professionals who care for people living with or at risk of HIV infection.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Devise HIV management strategies based on the results of recent clinical studies of established antiretroviral agents

  • Appropriately apply and counsel patients regarding the clinical role(s) of new and investigational ART regimens and strategies

  • Integrate the latest scientific findings to develop and optimize effective HIV prevention interventions

Disclosure

Primary Author

Darrell H. S. Tan, MD, FRCPC, PhD: researcher: Gilead, GlaxoSmithKline.